Published in J Acquir Immune Defic Syndr on May 01, 2013
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women | NCT00074425
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition. Antiviral Res (2014) 0.91
HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sex Transm Infect (2014) 0.88
Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study. PLoS One (2015) 0.79
Evaluation of vaginal drug levels and safety of a locally administered glycerol monolaurate cream in rhesus macaques. J Pharm Sci (2017) 0.75
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One (2008) 3.45
Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis (2004) 3.36
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One (2007) 2.41
Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA (2002) 1.98
Challenges to HIV prevention--seeking effective measures in the absence of a vaccine. N Engl J Med (2008) 1.53
Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol (2009) 1.52
Fourteen-day safety and acceptability study of the universal placebo gel. Contraception (2006) 1.27
Will microbicide trials yield unbiased estimates of microbicide efficacy? Contraception (2005) 1.23
WHO/CONRAD technical consultation on nonoxynol-9, World Health Organization, Geneva, 9-10 October 2001: summary report. Reprod Health Matters (2002) 1.10
The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One (2008) 1.06
Randomised trials of HIV prevention. Lancet (2007) 1.02
The use of the diaphragm instead of condoms in a phase III diaphragm trial. AIDS Behav (2008) 1.00
Preventing sexual transmission of HIV: anti-HIV bioregulatory and homeostatic components of commercial sexual lubricants. J Biol Regul Homeost Agents (2005) 1.00
The effect of polycarbophil gel (Replens) on bacterial vaginosis: a pilot study. Eur J Obstet Gynecol Reprod Biol (2006) 0.84
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Cranial drawers? Vet Rec (2009) 3.19
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Microbicide acceptability research: current approaches and future directions. Soc Sci Med (2005) 2.54
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One (2013) 2.39
Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr (2004) 2.39
Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis (2004) 2.29
The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt) (2003) 2.03
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00
In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr (2005) 1.99
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr (2008) 1.91
Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis (2002) 1.88
Study design and participation rates of the New York City Health and Nutrition Examination Survey, 2004. Prev Chronic Dis (2006) 1.83
HIV incidence among women of reproductive age in Malawi and Zimbabwe. Sex Transm Dis (2006) 1.75
Fertility intentions of HIV-1 infected and uninfected women in Malawi: a longitudinal study. AIDS Behav (2009) 1.73
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav (2013) 1.72
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav (2011) 1.68
HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med (2013) 1.59
Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS (2006) 1.51
Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. AIDS (2006) 1.48
Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr (2007) 1.46
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One (2010) 1.46
C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes (2009) 1.45
Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. BMJ (2003) 1.45
Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS (2012) 1.41
Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trial. AIDS Behav (2013) 1.32
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr (2015) 1.32
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr (2003) 1.30
Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sex Transm Dis (2010) 1.29
Combined impact of sexual risk behaviors for HIV seroconversion among women in Durban, South Africa: implications for prevention policy and planning. AIDS Behav (2011) 1.28
Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr (2010) 1.27
The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS (2012) 1.26
Selective processing of smoking-related cues in current smokers, ex-smokers and never-smokers on the modified Stroop task. J Psychopharmacol (2003) 1.21
Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles. J Infect Dis (2007) 1.20
Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother (2013) 1.16
Novel strategies implemented to ensure high participant retention rates in a community based HIV prevention effectiveness trial in South Africa and Zimbabwe. Contemp Clin Trials (2009) 1.15
Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ (2004) 1.15
Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe. AIDS Behav (2012) 1.12
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One (2013) 1.11
Patients' awareness of and attitudes toward gifts from pharmaceutical companies to physicians. Int J Health Serv (2009) 1.10
HIV incidence among non-pregnant women living in selected rural, semi-rural and urban areas in KwaZulu-Natal, South Africa. AIDS Behav (2012) 1.10
"We have our protector": misperceptions of protection against HIV among participants in a microbicide efficacy trial. Am J Public Health (2006) 1.09
Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa. AIDS Behav (2009) 1.08
The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: a cohort study. BMJ Open (2012) 1.07
The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res (2006) 1.07
A drug is effective if better than a harmless control. Nature (2005) 1.06
Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. AIDS Res Hum Retroviruses (2007) 1.06
Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): a possible mechanism of metabolic neuropathies. J Biol Chem (2012) 1.06
Patterns and predictors of adherence to diaphragm use in a phase III trial in sub-Saharan Africa: a trajectory analysis. J Acquir Immune Defic Syndr (2009) 1.05
Geoadditive models to assess spatial variation of HIV infections among women in local communities of Durban, South Africa. Int J Health Geogr (2011) 1.05
Male circumcision for HIV prevention: clinical practices and attitudes among healthcare providers in South Africa and Zimbabwe. Sex Transm Dis (2012) 1.03
Cesium migration in Hanford sediment: a multisite cation exchange model based on laboratory transport experiments. J Contam Hydrol (2003) 1.03
Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa. J Acquir Immune Defic Syndr (2007) 1.02
Hereditary hyperferritinemia-cataract syndrome: prevalence, lens morphology, spectrum of mutations, and clinical presentations. Arch Ophthalmol (2003) 1.01
Intermittent intravaginal antibiotic treatment of bacterial vaginosis in HIV-uninfected and -infected women: a randomized clinical trial. PLoS Clin Trials (2007) 1.01
The use of the diaphragm instead of condoms in a phase III diaphragm trial. AIDS Behav (2008) 1.00
Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064). AIDS Patient Care STDS (2014) 0.99
Human immunodeficiency virus (HIV) infection during pregnancy induces CD4 T-cell differentiation and modulates responses to Bacille Calmette-Guérin (BCG) vaccine in HIV-uninfected infants. Immunology (2009) 0.99
The role of anterior deltoid reeducation in patients with massive irreparable degenerative rotator cuff tears. J Shoulder Elbow Surg (2008) 0.99
Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One (2013) 0.99
The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir Ther (2011) 0.98
Perceptions of reimbursement for clinical trial participation. J Empir Res Hum Res Ethics (2011) 0.98
African women recently infected with HIV-1 and HSV-2 have increased risk of acquiring Neisseria gonorrhoeae and Chlamydia trachomatis in the Methods for Improving Reproductive Health in Africa trial. Sex Transm Dis (2011) 0.97
Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS (2015) 0.96
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP. Dev World Bioeth (2013) 0.96
High-risk human papillomavirus is associated with HIV acquisition among South African female sex workers. Infect Dis Obstet Gynecol (2011) 0.96
Natural history and risk factors associated with early and established HIV type 1 infection among reproductive-age women in Malawi. Clin Infect Dis (2008) 0.96
Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis (2014) 0.96
Risk factors for incidence of sexually transmitted infections among women in South Africa, Tanzania, and Zambia: results from HPTN 055 study. Sex Transm Dis (2009) 0.96
User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa. AIDS Care (2011) 0.95
Gestational age assessment in malaria pregnancy cohorts: a prospective ultrasound demonstration project in Malawi. Malar J (2013) 0.95
Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding". AIDS Behav (2015) 0.95
Duet for menstrual protection: a feasibility study in Zimbabwe. Contraception (2009) 0.95
Patients' satisfaction with reproductive health services at Gogo Chatinkha Maternity Unit, Queen Elizabeth Central Hospital, Blantyre, Malawi. Malawi Med J (2010) 0.95
Willingness of clinicians to integrate microbicides into HIV prevention practices in southern Africa. AIDS Behav (2012) 0.92
Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis (2012) 0.92
Contraception use and effectiveness among women in a trial of the diaphragm for HIV prevention. Contraception (2011) 0.92
An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc (2010) 0.92
Microbicide acceptability: insights for future directions from providers and policy makers. AIDS Educ Prev (2008) 0.91